GB-115 vs PE-22-28
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ranquilon, N-phenylacetyl-L-prolylglycine ethyl ester
A dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia with completed Phase 3 trials for anxiety. Users report significant improvements in focus, attention, and ADHD-like symptoms.
Also: PE22-28, Spadin Analog
A synthetic heptapeptide (7 amino acids) derived from Spadin, a naturally occurring antidepressant peptide. PE-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of Spadin. Works by blocking TREK-1 potassium channels in the brain.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- GB-115 has stronger research evidence (Human Trials) compared to PE-22-28 (Animal Studies).
Detailed Comparison
| Attribute | GB-115 | PE-22-28 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GB-115 works by blocking central cholecystokinin-1 (CCK-1) receptors in the brain. CCK is involved in anxiety, panic responses, and cognitive modulation. By antagonizing these receptors, GB-115 reduces anxiety while improving attention, processing speed, and reaction time. It also modulates dopaminergic pathways involved in focus and motivation. | PE-22-28 selectively blocks TREK-1 (TWIK-related potassium channel 1), a two-pore domain potassium channel highly expressed in the brain. TREK-1 inhibition increases neuronal excitability and enhances serotonergic and noradrenergic neurotransmission. This mechanism is distinct from traditional SSRIs and produces rapid-onset antidepressant effects in preclinical studies. |
| Common Dosing | 6 mg daily (2 mg three times daily) 2-3 times daily (morning, afternoon, evening) | 100-300 mcg intranasal or subcutaneous Once daily |
| Administration | Oral tablets or sublingual | Intranasal or subcutaneous injection |
| Typical Duration | 21+ days in clinical trials, effects noted by day 7 | Research protocols vary, often 2-4 weeks |
| Best Time to Take | Morning and throughout the day | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Clinical studies in patients with Generalized Anxiety Disorder (GAD) showed GB-115 (6mg/day) significantly improved reaction time, attention, and processing speed within 7 days of treatment. A 21-day trial with 31 patients demonstrated anxiolytic effects comparable to benzodiazepines without sedation or dependency. Currently in Phase II/III trials (NCT05586789) for anxiety disorders. Anecdotal reports suggest benefits for ADHD symptoms, though direct ADHD trials are pending. | Animal studies demonstrate significant antidepressant and anxiolytic effects within days of administration (faster than traditional SSRIs which take weeks). PE-22-28 shows improved stability compared to full Spadin while maintaining efficacy. Research indicates potential for treatment-resistant depression. No human clinical trials conducted yet. |
Frequently Asked Questions: GB-115 vs PE-22-28
What is the difference between GB-115 and PE-22-28?
GB-115 is a cognitive peptide that a dipeptide anxiolytic and nootropic that acts as a cck-1 (cholecystokinin) receptor antagonist. developed in russia with completed phase 3 trials for anxiety. users report significant improvements in focus, attention, and adhd-like symptoms. PE-22-28 is a cognitive peptide that a synthetic heptapeptide (7 amino acids) derived from spadin, a naturally occurring antidepressant peptide. pe-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of spadin. works by blocking trek-1 potassium channels in the brain. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GB-115 or PE-22-28?
Neither is universally "better" - the choice depends on your specific goals. GB-115 is typically used for cognitive purposes, while PE-22-28 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GB-115 and PE-22-28 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GB-115 and PE-22-28 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.